Brief: Palatin Technologies Announces Reinitiation Of Enrollment Of Phase 2 Study With Pl9643 For Treatment Of Dry Eye Disease
08/07/2020 12:39
July 8 (Reuters) - Palatin Technologies Inc PTN.A :
* PALATIN TECHNOLOGIES, INC. ANNOUNCES REINITIATION OF
ENROLLMENT
OF PHASE 2 STUDY WITH PL9643 FOR THE TREATMENT OF DRY EYE
DISEASE
* PALATIN TECHNOLOGIES INC - DATA READOUT TARGETED FOR Q4 OF
CALENDAR YEAR 2020
* PALATIN TECHNOLOGIES - PATIENT ENROLLMENT FOR PL9643
PHASE 2
CLINICAL STUDY IS CURRENTLY EXPECTED TO BE COMPLETE WITHIN NEXT
30-45 DAYS
Source text for Eikon: ID:nPn1DZbNba
Further company coverage: PTN.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Palatin Technologies
See all newsPalatin Technologies Inc reports results for the quarter ended March 31 - Earnings Summary
Palatin Technologies Inc expected to post a loss of $1.20 a share - Earnings Preview
Palatin Technologies Q2 revenue rises yr/yr, net loss widens
Brief: Palatin Announces 1-For-50 Reverse Stock Split
Brief: Palatin Announces Positive Preclinical Efficacy Data For Oral MC4R Agonist PL7737 In Animal Model Of Obesity